Dalmonte Thomas, Andreani Giulia, Rudelli Cecilia, Isani Gloria
Department of Veterinary Medical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Phytother Res. 2024 Dec;38(12):5672-5689. doi: 10.1002/ptr.8336. Epub 2024 Sep 23.
Knee osteoarthritis (OA) has recently been ranked as the 11th highest contributor to global disability. More than 40% of patients use complementary and alternative medicine including supplements containing phytoextracts with anti-inflammatory properties as those from the Boswellia genus. The aim of this meta-analysis was to evaluate the efficacy of phytoextracts from the oleogum resin of the Boswellia genus as supplementation for patients affected by knee OA. Four electronic databases were used for the research and PRISMA statements were followed throughout the study. The following inclusion criteria were used: (a) the subjects of the study were humans with a diagnosis of knee OA reported by medical staff; (b) randomization and the presence of control (placebo, negative or positive control), and (c) outcomes reported with WOMAC and/or visual analog scale (VAS) score. Publication bias was assessed with a funnel plot and through the Egger test. The Jadad scale was used in order to assess the quality of the studies included. The statistical heterogeneity was assessed using I statistics. Results of meta-analysis and subgroup analysis were reported using a forest plot. A total of 13 studies involving 850 (WOMAC) and 1185 (VAS) patients met the inclusion criteria. The meta-analysis did not detect a significant effect of the use of Boswellia extracts between the control and the treatment groups due to the high heterogeneity of the studies (p = 0.0865 for WOMAC) and (p = 0.3966 VAS). However, the subsequent subgroup analysis demonstrated the significant beneficial effect of Boswellia extracts in the treatment of knee OA with respect to a placebo (lower WOMAC score in the treatment groups). This was also confirmed in the meta-regression applied to the WOMAC scores. This is an important finding as people exposed to NSAID-related adverse effects could benefit from the use of Boswellia extracts. However, further high-quality studies are needed to establish the clinical efficacy of extracts from the genus Boswellia.
膝关节骨关节炎(OA)最近被列为全球残疾的第11大主要原因。超过40%的患者使用补充和替代医学,包括含有具有抗炎特性的植物提取物的补充剂,如来自乳香属的提取物。本荟萃分析的目的是评估乳香属油树脂中的植物提取物作为膝关节OA患者补充剂的疗效。研究使用了四个电子数据库,并在整个研究过程中遵循PRISMA声明。采用以下纳入标准:(a)研究对象为经医务人员诊断为膝关节OA的人类;(b)随机分组且有对照(安慰剂、阴性或阳性对照),以及(c)使用WOMAC和/或视觉模拟量表(VAS)评分报告结果。通过漏斗图和Egger检验评估发表偏倚。使用Jadad量表评估纳入研究的质量。使用I统计量评估统计异质性。使用森林图报告荟萃分析和亚组分析的结果。共有13项研究涉及850名(WOMAC)和1185名(VAS)患者符合纳入标准。由于研究的高度异质性,荟萃分析未发现乳香提取物在对照组和治疗组之间有显著效果(WOMAC的p = 0.0865)和(VAS的p = 0.3966)。然而,随后的亚组分析表明,相对于安慰剂,乳香提取物在治疗膝关节OA方面具有显著的有益效果(治疗组的WOMAC评分较低)。这在应用于WOMAC评分的荟萃回归中也得到了证实。这是一个重要的发现,因为接触非甾体抗炎药相关不良反应的人可能会从使用乳香提取物中受益。然而,需要进一步的高质量研究来确定乳香属提取物的临床疗效。